SCHEMBL3299804

SCHEMBL3299804

COc1ccc(CNc2nc3c(c(=O)n2-c2ccccc2)CN(C(=O)Nc2cccc(C(F)(F)F)c2)CC3)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
MAPT P10636 1/20 0.50
PRLHR P49683 8/20 0.48
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
CCNC P24863 1/20 0.46
CDK8 P49336 1/20 0.46
PRKAB2 O43741 1/20 0.43
PRKAG1 P54619 1/20 0.43
PRKAA2 P54646 1/20 0.43
PRKAA1 Q13131 1/20 0.43
PRKAG3 Q9UGI9 1/20 0.43
PRKAG2 Q9UGJ0 1/20 0.43
PRKAB1 Q9Y478 1/20 0.43
AKR1C3 P42330 1/20 0.42
AKR1C2 P52895 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
KDR P35968 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300072 0.92 PRLHR (0.53) LMNAMAPTPRLHRGAASMN1; SMN2
SCHEMBL3302520 0.92 PRLHR (0.47) LMNAMAPTPRLHRGAASMN1; SMN2
SCHEMBL3300866 0.91 PRLHR (0.44) MAPTPRLHRHSD17B10TSHRRECQL
SCHEMBL3301167 0.90 PRLHR (0.48) MAPTPRLHRKDRRECQL
SCHEMBL3299970 0.89 PRLHR (0.45) MAPTPRLHRRECQL
SCHEMBL3297793 0.89 PRLHR (0.50) PRLHR
SCHEMBL3297467 0.89 PRLHR (0.45) LMNAMAPTPRLHRGAASMN1; SMN2
SCHEMBL3299870 0.88 CDK1 (0.52) LMNAMAPTPRLHRSMN1; SMN2KDR
SCHEMBL3303208 0.88 PRLHR (0.51) LMNAMAPTPRLHRSMN1; SMN2
SCHEMBL3300847 0.88 PRLHR (0.51) PRLHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232282-B2 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-07-31 US disclosed
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-15 US disclosed
EP-2078719-A1 COMPOUND HAVING BICYCLIC PYRIMIDINE STRUCTURE AND PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2009-07-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093771-A1 Compound having bicyclic pyrimidine structure and pharmaceutical composition comprising the same GART, MGAT2, MGAT1 LMNA 510/4885MAPT 2514/4885PRLHR 3093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.